Trial Profile
Cerebrolysin REGistry Study in Stroke A Registry Study to Assess Practices, Safety and Effectiveness of Cerebrolysin in Routine Treatment of Acute Ischemic Stroke
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs FPF 1070 (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms CREGS-S
- Sponsors EVER Neuro Pharma
- 28 Mar 2022 Status changed from active, no longer recruiting to discontinued. Reason: The goal to match 1000 patients per group could not be achieved with reasonable effort and in reasonable time.
- 03 Aug 2020 Planned End Date changed from 1 Jul 2020 to 1 Dec 2020.
- 21 Oct 2019 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.